Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.43 |
| ▸ | MET | P08581 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 5/20 | 0.38 |
| ▸ | CDK1 | P06493 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | CDK3 | Q00526 | 2/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836423 | 1.00 | GSK3B (0.43) | GSK3BMETKDRCDK9CDK1 | |
| SCHEMBL29836417 | 0.96 | GSK3B (0.47) | GSK3BMETKDRCDK9CDK1 | |
| SCHEMBL21591765 | 0.96 | GSK3B (0.47) | GSK3BMETKDRCDK9CDK1 | |
| SCHEMBL21591793 | 0.92 | MAPK10 (0.43) | GSK3BMAPK14 | |
| SCHEMBL29836435 | 0.92 | MAPK10 (0.43) | GSK3BMAPK14 | |
| SCHEMBL21593200 | 0.88 | MAPK1 (0.39) | GSK3BMETKDRCDK9CDK1 | |
| SCHEMBL29836475 | 0.85 | HRH3 (0.41) | GSK3BMET | |
| SCHEMBL21593249 | 0.85 | HRH3 (0.41) | GSK3BMET | |
| SCHEMBL21593250 | 0.84 | BRAF (0.36) | GSK3BMETKDRMAP4K1 | |
| SCHEMBL29836438 | 0.84 | BRAF (0.36) | GSK3BMETKDRMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | claimed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | claimed |
| EP-3807273-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2021-04-21 | — | — | EP | claimed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | claimed |
| EP-3807273-B1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2022-08-03 | — | — | EP | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | GSK3B 84/4885MET 2620/4885KDR 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.